Fig. 1.

ABT-737 as a monotherapy is ineffective in human glioma cells. A, LN18, LN229, LNZ428, U87, and LNZ308 cells were exposed to the indicated concentrations of ABT-737 for 24, 48, and 72 h. The relationship between ABT-737 and cell numbers was assessed semiquantitatively by spectrophotometric measurement of MTS bioreduction in five established malignant human glioma cell lines. Control cells were treated with equivalent concentrations of vehicle (DMSO). B, LN18, LN229, LNZ428, U87, and LNZ308 cells were treated with the indicated concentrations of ABT-737 for 24 h. Control cells received DMSO. Clonogenic assay was performed as described under Materials and Methods.